Drug Sales Trends for PAROEX

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for PAROEX

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
PAROEX			2022
PAROEX			2021
PAROEX			2020
PAROEX			2019
PAROEX			2018
PAROEX			2017

PAROEX Market Analysis, Patent Status, Competitive Landscape, and Sales Projections

Last updated: September 8, 2026

PAROEX is a prescription 0.12% chlorhexidine gluconate oral rinse marketed for reducing gingival inflammation and dental plaque associated with gingivitis. Its commercial opportunity is concentrated in dental prescriptions, periodontal maintenance, post-procedure care, and institutional dental channels. The product has limited differentiation from generic chlorhexidine gluconate oral rinses, so market share depends primarily on dentist preference, distributor access, formulary positioning, packaging, and price.

Public sources do not disclose PAROEX-specific revenue. A bottom-up model indicates a plausible U.S. net-sales range of approximately $8 million to $25 million annually for the branded product, with a base case near $15 million. The broader U.S. prescription chlorhexidine oral-rinse market is materially larger because it includes generic products and competing brands.

What is PAROEX and who markets it?

PAROEX is an oral rinse containing chlorhexidine gluconate at a concentration of 0.12%. The U.S. product is associated with Sunstar Americas, Inc. and is supplied as a prescription dental product in multidose bottles, including a commonly marketed 473 mL size.[1]

Attribute	PAROEX profile
Active ingredient	Chlorhexidine gluconate
Concentration	0.12%
Dosage form	Oral rinse
U.S. regulatory status	Prescription drug
Primary indication	Gingivitis
Main prescribers	General dentists, periodontists, oral surgeons
Main channel	Dental offices, pharmacies, dental distributors
Primary competitors	Generic chlorhexidine gluconate oral rinses, Peridex, other dental antiseptic rinses
Commercial differentiation	Brand recognition, supply reliability, distributor access, packaging and customer support

The FDA labeling for chlorhexidine gluconate oral rinse describes twice-daily use after brushing, with patients instructed to rinse and expectorate rather than swallow the product.[1] The product is not positioned as a systemic therapy and is not a replacement for mechanical plaque control.

What is the FDA regulatory status of PAROEX?

PAROEX is an FDA-approved prescription oral rinse for gingivitis. The relevant regulatory framework is the approved drug application for chlorhexidine gluconate oral rinse, rather than an over-the-counter mouthwash monograph.[1]

The product’s commercial status reflects several regulatory characteristics:

• It is a small-molecule drug, not a biologic.
• It does not require biosimilar competition.
• Generic manufacturers can seek approval through an abbreviated new drug application, or ANDA.
• Substitution and purchasing decisions are strongly affected by state pharmacy law, payer policy, dental-office dispensing practices, and wholesaler availability.
• Safety considerations include tooth and tongue staining, increased calculus formation, altered taste, and hypersensitivity reactions.[1]

The FDA-approved indication is narrower than broad consumer mouthwash positioning. That limits direct substitution with cosmetic or over-the-counter antiseptic rinses, but it also restricts promotional claims.

What patents protect PAROEX and when does it lose exclusivity?

The commercial patent risk for PAROEX is low because chlorhexidine gluconate oral rinse is an established active ingredient and the core formulation is mature. The principal competitive threat is generic approval and pricing, not the expiry of a high-value compound patent.

Orange Book status

The FDA Orange Book is the controlling source for current patents and regulatory exclusivity associated with an approved drug application.[2] Publicly available product information does not establish a meaningful, durable patent barrier around the active ingredient or the basic 0.12% oral-rinse formulation.

The relevant protection profile is:

Protection category	PAROEX assessment
New chemical entity exclusivity	Not applicable to the mature chlorhexidine active ingredient
Compound patent	No commercially relevant blocking compound patent expected
Basic formulation patent	Weak or expired for a conventional aqueous 0.12% rinse
Method-of-use patent	Possible historic or limited scope, but unlikely to block routine generic gingivitis use
Device or packaging patent	Potentially relevant to a specific package, not the active pharmaceutical product
Regulatory exclusivity	No publicly established long-duration exclusivity barrier
Biosimilar exclusivity	Not applicable

A current Orange Book review is necessary for definitive patent numbers and listed expiration dates. The economic conclusion is unchanged: PAROEX should be analyzed as a mature prescription product exposed to generic competition rather than as a product protected by a late-life patent estate.

How many patents cover PAROEX?

The number of commercially meaningful patents is likely small. A conventional chlorhexidine gluconate oral rinse does not require a complex delivery system, device platform, biologic manufacturing process, or specialized active pharmaceutical ingredient.

Potentially relevant patent categories include:

1. Specific excipient combinations designed to improve taste or stability.
2. Packaging configurations, including unit-dose or dispensing systems.
3. Manufacturing controls for chlorhexidine concentration, pH, impurities, or preservative systems.
4. Narrow methods of use involving dental procedures or specific patient populations.
5. Formulations designed to reduce staining or improve tolerability.

These rights would generally create incremental protection. They would not necessarily prevent an ANDA applicant from launching a conventional chlorhexidine gluconate oral rinse using a different formulation or package.

What formulations are protected by PAROEX?

The commercial formulation is a conventional aqueous chlorhexidine gluconate rinse. The formulation value is operational rather than technologically differentiated. Generic competitors can often develop a therapeutically equivalent product using the same active ingredient and a different inactive-ingredient profile.

Formulation-related commercial advantages may include:

• Taste acceptability.
• Stability during shelf life.
• Consistent chlorhexidine concentration.
• Reduced precipitation or discoloration.
• Bottle design and dispensing accuracy.
• Compatibility with dental-office inventory systems.
• Lower incidence of leakage during shipping.
• Availability in different package sizes.

The principal formulation weakness is that the product’s clinical and regulatory identity is easy for prescribers to understand and relatively easy for generic manufacturers to replicate. A formulation patent would have the greatest value only if it delivered a measurable clinical or adherence advantage that generic products could not readily design around.

Which companies are challenging PAROEX?

Generic pharmaceutical manufacturers are the primary competitive challengers. The relevant group includes suppliers of chlorhexidine gluconate oral rinse and dental antiseptic products that compete through pharmacy substitution, wholesaler contracts, or direct dental distribution.

Competitive pressure can arise from:

• ANDA approvals for therapeutically equivalent 0.12% chlorhexidine oral rinses.
• Authorized generic or private-label offerings.
• Contract-manufactured dental products.
• Hospital and dental-group formulary tenders.
• Low-cost imports or distributor-controlled products.
• Consumer rinses that compete for post-procedure and gingivitis-related use, even without identical labeling.

No prominent biosimilar challenge exists because PAROEX is a small-molecule oral rinse. A Paragraph IV challenge would be commercially relevant only if the Orange Book contained an unexpired patent listed against the relevant product. For a mature conventional chlorhexidine rinse, a generic applicant is more likely to rely on a certification that avoids or does not infringe any listed patent than to pursue a high-value patent litigation strategy.

What is the Paragraph IV and litigation risk for PAROEX?

The expected litigation risk is low to moderate, depending on current Orange Book listings. The product does not appear to present the characteristics that typically support expensive pharmaceutical patent litigation: there is no new molecular entity, no biologic manufacturing platform, and no complex delivery device.

Risk area	Assessment
Compound patent litigation	Low
Formulation litigation	Low to moderate
Method-of-use litigation	Low
ANDA Paragraph IV activity	Possible but likely limited in value
Launch-at-risk exposure	Low to moderate
Supply-chain competition	High
Price erosion after generic entry	High

If an ANDA applicant files a Paragraph IV certification against a listed formulation or method patent, the brand owner could bring a Hatch-Waxman action under 21 U.S.C. § 271(e)(2).[3] The commercial value of such litigation would depend on the patent’s remaining term, the number of generic applicants, and whether the asserted claims cover the reference product itself rather than a narrow manufacturing or packaging feature.

No widely reported, high-value PAROEX patent settlement is established in the public sources cited here. The absence of a major settlement is consistent with the product’s mature chemistry and limited patent leverage.

How large is the market for prescription chlorhexidine oral rinse?

The market has three overlapping segments:

1. Prescription dental treatment for gingivitis.
2. Periodontal and oral-surgery use.
3. Postoperative or institutional use in hospitals, dental clinics, and long-term-care settings.

The highest-value customers are dental practices and dental service organizations that purchase in volume or influence product selection. Retail pharmacy sales are more exposed to generic substitution and payer reimbursement controls.

The market is mature. Volume growth is likely to track:

• Dental visit growth.
• Periodontal disease prevalence.
• Expansion of dental service organizations.
• Procedure volume in oral surgery and periodontics.
• Prescription and reimbursement trends.
• Availability of lower-priced generic products.

The American Dental Association identifies gingivitis and periodontal disease as common oral-health conditions, supporting persistent clinical demand for plaque-control treatments.[4] Demand, however, is episodic. Many patients receive a short course after a procedure rather than chronic therapy.

How does PAROEX compare with Peridex and generic chlorhexidine?

PAROEX competes most directly with Peridex and generic chlorhexidine gluconate oral rinses. The products share the same active ingredient and concentration in the principal U.S. prescription market.

Criterion	PAROEX	Peridex	Generic chlorhexidine rinse
Active ingredient	Chlorhexidine gluconate	Chlorhexidine gluconate	Chlorhexidine gluconate
Typical strength	0.12%	0.12%	0.12%
Regulatory status	Prescription	Prescription	Prescription
Clinical differentiation	Limited	Limited	Limited
Price position	Brand or branded-generic	Brand	Lowest-cost segment
Dental-office recognition	Established	Established	Supplier-dependent
Generic substitution risk	High	High	Not applicable
Patent leverage	Limited	Limited	N/A
Main advantage	Distribution and brand continuity	Legacy brand recognition	Price

PAROEX can retain share when dentists value reliable supply, established ordering channels, or a familiar product name. It is vulnerable when payers, dental groups, or pharmacies prioritize acquisition cost.

What are PAROEX sales and revenue projections?

PAROEX-specific sales are not publicly reported by Sunstar in a way that permits direct verification. The following forecast is a bottom-up commercial model rather than a reported company figure.

Base assumptions

• U.S. annual treated prescriptions or equivalent treatment courses: 8 million to 14 million.
• Average commercial units per course: approximately one 473 mL bottle, with variation by dosing duration.
• Branded PAROEX share of prescription chlorhexidine volume: 5% to 12%.
• Net revenue per branded bottle after discounts and channel deductions: $14 to $24.
• International revenue contribution: 10% to 25% of total sales, depending on country registrations and distributor reach.
• Annual market growth before price erosion: 1% to 3%.
• Annual net-price pressure in competitive channels: 2% to 5%.

U.S. PAROEX forecast

Scenario	Annual branded volume	Net revenue per unit	Estimated U.S. sales
Downside	400,000 units	$14	$5.6 million
Base case	750,000 units	$20	$15.0 million
Upside	1.2 million units	$24	$28.8 million

A reasonable base-case forecast is approximately $15 million in current annual U.S. PAROEX sales, with a five-year trajectory that remains broadly flat to modestly declining unless the owner improves distribution, secures dental-group contracts, or introduces differentiated packaging.

Five-year revenue projection

Year	Downside	Base case	Upside
Year 1	$5.6 million	$15.0 million	$28.8 million
Year 2	$5.2 million	$15.0 million	$29.1 million
Year 3	$4.8 million	$14.8 million	$29.1 million
Year 4	$4.4 million	$14.5 million	$29.0 million
Year 5	$4.0 million	$14.2 million	$28.7 million

The base case assumes continued generic price competition and no major patent event. The upside case requires strong dental-distributor execution, stable brand preference, and limited additional generic penetration. The downside case reflects broader substitution and loss of dental-group purchasing contracts.

What generic entry risks exist for PAROEX?

Generic entry is the central commercial risk. The product’s exposure is high because:

• The active ingredient is mature.
• The formulation is relatively simple.
• The clinical indication is well established.
• Prescribers can identify therapeutic alternatives easily.
• Pharmacy and institutional buyers have strong incentives to reduce cost.
• Dental practices may switch products without changing treatment protocols.

Generic entry does not eliminate PAROEX demand. Brand volume can persist in offices that dispense directly, in accounts with established procurement contracts, and among prescribers who value consistent supply. The likely effect is lower net price and reduced branded share rather than immediate disappearance.

What manufacturing and intellectual-property barriers protect PAROEX?

Manufacturing barriers are modest. Production requires controlled compounding, active-ingredient assay, impurity control, microbiological quality, packaging validation, and stability testing. These requirements impose regulatory costs but do not create a major barrier for established generic manufacturers.

The strongest practical barriers are commercial:

• Dental-distributor relationships.
• National wholesaler access.
• Reliable inventory.
• FDA-compliant manufacturing.
• Customer service for dental practices.
• Ability to support private-label and institutional accounts.
• Consistent bottle, cap, label, and shipping performance.

The weakest barriers are molecular and formulation-based. A competitor can generally reproduce the therapeutic concept without duplicating every inactive ingredient or package component.

What licensing deals affect PAROEX?

No major public licensing transaction tied specifically to PAROEX is established in the cited sources. Commercial rights may be distributed through manufacturer, distributor, or private-label arrangements, but these arrangements are distinct from a high-value technology license.

A licensing transaction involving PAROEX would likely focus on:

• Regional commercialization rights.
• Dental-distributor networks.
• Contract manufacturing.
• Private-label supply.
• Formulation or packaging improvements.
• International registrations.

The absence of a disclosed licensing transaction limits the ability to assign separate milestone or royalty value to the brand.

What is the geographic opportunity for PAROEX?

The United States is the most important market for a prescription chlorhexidine oral rinse because of established dental prescribing and a large dental-distribution infrastructure. International opportunity depends on local product registrations, prescription classification, reimbursement, and competition from local chlorhexidine products.

Region	Commercial outlook
United States	Largest identifiable opportunity; high generic pressure
Canada	Smaller market; regulatory and reimbursement constraints
Western Europe	Mature dental markets; country-specific registration required
Latin America	Potentially high chlorhexidine use; strong local-brand competition
Asia-Pacific	Large patient base but fragmented pricing and regulatory pathways
Middle East and Africa	Institutional and dental-clinic demand; distributor-led access

International expansion can increase volume but may lower average net price. Local generics and branded chlorhexidine products frequently compete on cost.

Key Takeaways

• PAROEX is a prescription 0.12% chlorhexidine gluconate oral rinse used primarily in dental care.
• Its commercial position is based on brand, distribution, supply reliability, and dental-office access rather than strong patent protection.
• The product is a small molecule and has no biosimilar risk.
• Generic substitution is the principal threat to revenue and margin.
• A reasonable modeled U.S. sales range is $6 million to $29 million annually, with a base case near $15 million.
• Five-year sales are likely to be flat to moderately declining without new channel contracts or product differentiation.
• Formulation and packaging rights may provide incremental protection but are unlikely to block conventional generic entry.
• No major public PAROEX-specific patent settlement or licensing transaction is established in the cited record.
• The most valuable commercial assets are dental-distributor relationships, institutional contracts, and dependable manufacturing capacity.

FAQs

Is PAROEX the same as chlorhexidine mouthwash?

PAROEX is a branded prescription formulation of chlorhexidine gluconate oral rinse, commonly supplied at 0.12%. Generic chlorhexidine rinses may contain the same active ingredient and concentration but can differ in inactive ingredients, packaging, price, and supplier.

Is PAROEX protected by a new-drug patent?

PAROEX is not expected to have meaningful remaining protection from a compound patent because chlorhexidine is an established active ingredient. Any relevant protection would more likely involve a narrow formulation, manufacturing, packaging, or method-of-use claim.

Can pharmacies automatically substitute generic chlorhexidine for PAROEX?

Substitution depends on the product’s therapeutic-equivalence designation, state pharmacy law, payer requirements, prescriber instructions, and the dispensing pharmacy. Dental offices that purchase and dispense the product may make the substitution decision directly.

Does PAROEX have a long-term exclusivity period?

PAROEX does not have the exclusivity profile associated with a newly approved chemical entity or biologic. Commercial exclusivity is primarily determined by brand preference, distribution, contracts, and the timing and depth of generic competition.

What would increase PAROEX sales most effectively?

The strongest commercial levers are dental-service-organization contracts, direct dental-office dispensing, reliable wholesaler inventory, competitive pricing, and a formulation or package improvement that delivers a clear adherence or tolerability advantage.

References

1. U.S. Food and Drug Administration. (n.d.). Chlorhexidine gluconate oral rinse prescribing information. FDA labeling database.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. United States Code. (2024). 35 U.S.C. § 271(e)(2): Infringement of patents relating to drugs and biological products. Legal Information Institute, Cornell Law School.

4. American Dental Association. (n.d.). Gum disease. https://www.ada.org/resources/research/science-and-research-institute/oral-health-topics/gum-disease